Herbal products and traditional medicines are estimated to be the primary means of healthcare for up to 80% of the population in some Asian and African countries, with herbal treatments being the most popular[@b1]. Popularity for use of herbal products as complementary medication in western countries has risen dramatically in recent years, and in the United States the use of herbal products is estimated at between 20-38% among adults[@b2][@b3][@b4] while in some European countries this estimate rises to a range of 50--70%[@b5]. However, the lack of tight regulation of herbal products (production, purity and quality), unsustainable health claims and the lack of defined mechanisms of action prevents the incorporation of many herbal treatments into mainstream medicine[@b2].

Oxymatrine, classified as a quinolizidine alkaloid, is an herbal product derived from the root of the *Sophora flavescens* Ait. plant[@b6]. Oxymatrine has been primarily used in China for the treatment of various human illnesses such as hepatitis B infections and liver fibrosis[@b7][@b8]. It has also been reported to provide a protective effect in various animal models of ischemia and reperfusion (I/R)-induced liver, heart, and intestinal injury[@b9][@b10][@b11]. The molecular pathways by which oxymatrine mediates its protective effects remain unclear but appear to involve both inhibition of p38MAPK phosphorylation[@b11][@b12], and decreased NF-κB subunit p65 protein expression[@b13][@b14]. In addition to the aforementioned protection from I/R-induced injury, it was reported that oxymatrine administration decreased dextran sulfate sodium (DSS) induced colitis in rats[@b15], although the mechanism of action was not fully investigated.

Here we show that oxymatrine prevents LPS induced pro-inflammatory gene expression in bone marrow-derived dendritic cells (BMDC) and in intestinal epithelial cells (IEC). We demonstrate that oxymatrine dampens NF-κB activity by inhibiting LPS-induced nuclear translocation of p65, an effect independent of signal induced IκB phosphorylation/degradation. Importantly, oxymatrine ameliorates DSS-induced weight loss, histopathological scores and expression of *Il1β* and *Il6* pro-inflammatory gene expression without global inhibition of NF-κB transcriptional activity.

Results
=======

Oxymatrine inhibits LPS-induced pro-inflammatory cytokine expression in IECs and BMDCs
--------------------------------------------------------------------------------------

To investigate the effects of oxymatrine on pro-inflammatory cytokine production, we stimulated the rat intestinal epithelial cell (IEC)-6 line with LPS and treated cells using various concentrations of oxymatrine and measured expression of pro-inflammatory mediators. LPS-induced *Cxcl2*, *Tnfα* and *Il6* mRNA expression were significantly reduced in presence of oxymatrine (p \< 0.05) at 1 hr but only *Cxcl2* remained inhibited by 4 hr ([Fig. 1](#f1){ref-type="fig"}). LPS-induced //*1β* mRNA accumulation was unaffected by oxymatrine treatment ([Fig. 1](#f1){ref-type="fig"}). To ensure that cell death was not responsible for the decreased LPS-induced cytokine expression by oxymatrine, we performed a cell viability assay. No significant difference in cell mortality was noticed in cells treated with oxymatrine or co-treated with oxymatrine and LPS compared to control cells (\< 5% at 4 mg/ml) (data not shown).

In order to assess the effect of oxymatrine on immune cell activity, we generated BMDCs from WT mice. Analysis of the kinetics of LPS-induced *Il6* and *Tnf* mRNA accumulation in treated BMDCs showed that oxymatrine significantly inhibited *Il6* at 1 and 4 hr (p \< 0.01) and *Tnfα* at 4 hr of stimulation (p \< 0.01), while *Il1β* expression was unaffected ([Fig. 2](#f2){ref-type="fig"}). These findings indicate that oxymatrine prevents expression in a selective group of LPS-induced pro-inflammatory genes in both IEC and immune cells.

Oxymatrine prevents NF-κB activity without blocking IκBα phosphorylation and through inhibition of p65 nuclear translocation
----------------------------------------------------------------------------------------------------------------------------

Since LPS-induced *Cxcl2* is dependent on NF-κB activity[@b16], we investigated the impact of oxymatrine on this pathway. Using an NF-κB luciferase reporter assay we were able to show that oxymatrine significantly inhibited LPS-induced NF-κB transcriptional activity in a dose-dependent manner compared to control LPS stimulated cells (p \< 0.01) ([Fig. 3a](#f3){ref-type="fig"}). To identify the target of oxymatrine mediated NF-κB blockade, we investigated the status of IκBα phosphorylation/degradation. As expected, we observed a time-dependent increase in LPS-induced IκBα phosphorylation with concomitant degradation of total IκBα ([Fig. 3b](#f3){ref-type="fig"}). Interestingly, oxymatrine failed to prevent LPS-induced IκBα phosphorylation/degradation ([Fig. 3b](#f3){ref-type="fig"}). Reduced IκBα levels in LPS-stimulated, oxymatrine-treated cells at 90 min likely reflects the canonical nature of NF-κB signaling where blockade of the transcription factor leads to decreased expression of its inhibitor. In contrast, oxymatrine significantly reduced (p \< 0.05) LPS-induced p38MAPK phosphorylation in IECs at 60 min ([Fig. 3c](#f3){ref-type="fig"}).

Because NF-κB transcriptional activity was blocked independently of IκBα phosphorylation/degradation by oxymatrine treatment, we investigated the subcellular compartmentalization of the NF-κB transcriptional subunit p65. IEC-6 cells were treated with oxymatrine and stimulated with LPS for 0--60 min and p65 localization determined by immunofluorescent microscopy. Pre-treatment with oxymatrine followed by LPS stimulation resulted in a statistically significant reduction in LPS-induced p65 nuclear accumulation compared to LPS-only treated cells (∼40%; p \< 0.01) ([Fig. 4a--b](#f4){ref-type="fig"}). Although higher oxymatrine concentration (8 mg/mL) resulted in an increased inhibition (∼70%) of nuclear translocation ([Supplementary Fig. S1](#s1){ref-type="supplementary-material"}), this dosage was associated with cellular toxicity (data not shown). To confirm that oxymatrine prevents LPS-induced NF-κB binding to the *Cxcl2* promoter, we performed p65 chromatin immunoprecipitation using IEC-18 cells. LPS stimulation resulted in increased p65 binding to the *Cxcl2* gene promoter at 30 min, which then decreased by 60 min, a process inhibited by oxymatrine treatment ([Fig. 4c](#f4){ref-type="fig"}).

Oxymatrine ameliorates DSS-induced colitis
------------------------------------------

To determine the potential *in vivo* anti-inflammatory therapeutic effect of oxymatrine, we tested this herbal product using the DSS model of acute intestinal inflammation. DSS-induced weight-loss was approximately 15% in control mice, whereas mice treated with low (50 mg/kg) or high (200 mg/kg) doses of oxymatrine were significantly protected from weight-loss by d 9 ([Fig. 5a](#f5){ref-type="fig"}; p \< 0.05). Oxymatrine-injected control groups displayed no significant change in body weight ([Fig. 5a](#f5){ref-type="fig"}). Histological analysis revealed a significantly lower DSS injury score (p \< 0.05) with either low- or high-dose oxymatrine treatment ([Fig. 5b--c](#f5){ref-type="fig"}). We examined the levels of colonic inflammatory mediators in the different groups using real-time PCR and found a significant increase (p \< 0.05) of colonic *Il6*, *Il1β* and *Tnfα* mRNA accumulation in DSS-exposed mice ([Fig. 5d](#f5){ref-type="fig"}). Interestingly, DSS-induced *Il6* and *IL1β* mRNA accumulation were dose-dependently inhibited in oxymatrine-treated mice ([Fig. 5d](#f5){ref-type="fig"}). However, oxymatrine failed to inhibit DSS-induced TNF mRNA accumulation *in vivo* ([Fig. 5d](#f5){ref-type="fig"}). In addition, expression of the proliferative marker Ki-67 within intact colonic crypts decreased in DSS-exposed, oxymatrine-treated mice compared to untreated mice, suggesting an improved intestinal response ([Fig. 5e](#f5){ref-type="fig"}, [Supplementary Fig. S2](#s1){ref-type="supplementary-material"}). To gain more insight into *in vivo* NF-κB activation, we utilized NF-κB^EGFP^ reporter mice[@b17]. We observed increased EGFP expression in DSS-exposed NF-κB^EGFP^ mice compared to untreated mice ([Fig. 5f](#f5){ref-type="fig"}). NF-κB^EGFP^ mice exposed to DSS and treated with 200 mg/Kg oxymatrine showed similar pattern of EGFP expression to DSS-exposed mice ([Fig. 5f](#f5){ref-type="fig"}), and these expression levels were confirmed using western blot analysis ([Supplementary Fig. S2](#s1){ref-type="supplementary-material"}). These findings showed that oxymatrine reduced DSS-induced acute colitis, which correlates with attenuation of a selective set of pro-inflammatory cytokine gene expression, without globally preventing NF-κB activation.

Discussion
==========

The increasing interest in alternative medicine worldwide, especially naturally derived herbs and plant extracts, has spurned research into elucidating mechanism of action attributed to these compounds. Oxymatrine has shown promising beneficial effects in rodent models of I/R-induced liver, heart and lung injury[@b9][@b10][@b11]. In this study, we show that oxymatrine administration is able to significantly inhibit LPS-induced pro-inflammatory cytokine production in both immune and non-immune cells*.* We demonstrate that this inhibitory effect is associated with decreased NF-κB p65 nuclear migration. Finally, we validated the therapeutic potential of oxymatrine *in vivo* by showing that DSS-induced acute injury and colitis was attenuated by both low and high doses of the natural product. It is important to note that the intestinal epithelial cell layer is severely damaged upon DSS exposure, which causes a massive influx of bacteria and bacterial products (including LPS) into the normally segregated mucosal immune system. Therefore, the use of LPS *in vitro* is a means to reproduce the secondary effect of DSS *in vivo* (exposure of IEC and immune cells to bacterial products). This standard model of LPS stimulation *in vitro* to simulate and measure inflammatory responses, and the use of DSS-induced injury and colitis *in vivo* has been used in numerous reports[@b18][@b19][@b20][@b21][@b22][@b23] including studies published from our group[@b24][@b25].

An intriguing aspect of our study is that oxymatrine failed to inhibit LPS-induced IκBα phosphorylation/degradation, while blocking p65 nuclear translocation. This suggests that oxymatrine mediates its effect downstream of the classical IKK/IκB induced NF-κB activation. However, the p65 subunit contains a nuclear localization domain that is recognized by the karyopherin chaperone protein importin3α and interference between this chaperone protein and target p65 can impact nuclear shuttling[@b26]. Although we observed decreased p65/Importin α3 binding at steady state levels in the presence of oxymatrine, attempts to show increased interaction between the chaperone and p65 following LPS stimulation were unsuccessful (data not shown). Regardless of the exact mechanism of action, our study clearly demonstrates an inhibitory effect of oxymatrine on signal-induced p65 nuclear translocation at the level of protein localization (immunofluorescence) and DNA binding (ChIP assay). Previous studies by Fan H et al. showed that oxymatrine acts by reducing p65 protein expression in a rat model of TNBS-induced colitis[@b14], and a recent report shows that matrine, the related herbal product derived from the same plant, inhibits NF-κB in neurons and astrocytes in an IκB-dependent manner[@b27]. However, as we failed to observe either decreased p65 expression in oxymatrine-treated cells or inhibition of IκB-phosphorylation, we conclude that oxymatrine\'s main mechanism of action is sequestration of p65 in the cytoplasm, at least in IECs and BMDCs.

Oxymatrine shows no apparent global inhibitory effect on NF-κB transcriptional activity *in vivo* as seen in oxymatrine-treated, DSS-exposed NF-κB^EGFP^ mice. This is an important observation since NF-κB transcriptional activity is necessary to maintain epithelial barrier function and proper response to wound healing[@b28][@b29][@b30][@b31]. Though we see no global inhibition of NF-κB activity, mice treated with DSS and oxymatrine showed lower numbers of Ki-67^+^ cells within intact colonic crypts compared to untreated mice and far less than DSS treated mice. This difference may be indicative of the selective ability of oxymatrine to alter gene expression as we also observed a significant decrease in *Il6* and *Il1β* mRNA levels but sustained levels of *Tnfα* mRNA *in vivo*. Interestingly, TNFα exerts a protective function in DSS-induced colitis[@b32][@b33] and this may explain the beneficial impact of oxymatrine *in vivo*. Though oxymatrine blocks LPS-induced TNFα production in both IECs and BMDCs *in vitro*, the *in vivo* source of TNFα is not clear. Intestinal myofibroblasts[@b34] and NKT[@b35] cells are an important source of TNFα and could be unaffected by oxymatrine exposure. In addition, it is possible that the effect of oxymatrine on NF-κB *in vivo* could be coupled with effects on other signaling pathways such as p38MAPK[@b11][@b12] and acts to balance target gene transactivation lowering pro-inflammatory effects while preserving cyto-protective ones. A more comprehensive analysis (RNA-seq, gene array) would help understand the impact of oxymatrine-mediated transcriptional inhibition.

Although oxymatrine demonstrates a beneficial effect in the DSS-model of acute intestinal injury, it should be noted that not all herbal products ameliorate colitis. We recently showed that while another herbal product tomato lycopene extract (TLE) proved effective in reducing LPS-induced NF-κB activity *in vitro* by blocking IκBα phosphorylation and p65 nuclear translocation, it exacerbated pathology in the DSS-induced injury model of colitis[@b24]. This deleterious effect correlated with a strong increase in colonic NF-κB (EGFP) activity in NF-κB^EGFP^ mice, likely promoting expression of inflammatory cytokines by intestinal immune cells. Although TLE and oxymatrine both blocked NF-κB activity *in vitro*, the differential effects on colitis (protective vs deleterious) may be related to the extent of NF-κB inhibition. To that end, it is worth nothing that though the use of a higher oxymatrine concentration *in vitro* resulted in an increased inhibition of LPS-induced p65 nuclear translocation, this higher concentration was also associated with cellular toxicity. This suggests then that it is possible that NF-κB cyto-protective effect remains in oxymatrine-treated mice at the levels used in our study.

Although oxymatrine is considered to be safe and effective in treating Hepatitis B viral infections in China[@b36][@b37], additional investigation would be needed before this natural product could be considered for clinical use in the United States for treating intestinal inflammatory disorders. It would be important to demonstrate the efficacy of oxymatrine using various experimental models of chronic colitis such as the T-cell transfer or genetically engineered mice. In summary, our findings demonstrate that oxymatrine does possess anti-inflammatory effects *in vitro* and *in vivo*, acting at least in part through partial inhibition of NF-κB p65 nuclear translocation, which is independent of IκBα phosphorylation/degradation.

Methods
=======

Animal ethics statement
-----------------------

All animal procedures were performed in accordance with UNC institutional animal care and use committee (IACUC)-approved protocols. Mice were housed in specific pathogen-free (SPF) facilities at the University of North Carolina at Chapel Hill.

Cell culture and treatment
--------------------------

The non-transformed rat small intestinal cell lines IEC-6 (ATCC CRL 1592, American Tissue Culture Collection (ATCC), Manassas, VA) and IEC-18 (ATCC CRL 1589) were cultured as previously described[@b38]. IEC cells were plated in 6-well plates (2.5 × 10^5^) or 10 cm tissue culture plates (1 × 10^6^ cells/mL) for experiments. Bone marrow-derived dendritic cells (BMDCs) were generated from wild-type C57BL/6 mice as previously described[@b39] and used at day-5 of culture for experiments. BMDCs were plated at a density of 1 × 10^6^ cells/mL in 6-well plates.

All cells were washed with serum-free media and serum-starved for 2 hr prior to incubation with oxymatrine (98% purity, Narula Research, Chapel Hill, NC). Oxymatrine was reconstituted in saline and added to media for 1 hr prior to LPS stimulation. LPS (*Escherichia coli* serotype O111:B4, Sigma-Aldrich, St. Louis, MO) was used at various concentrations to stimulate IECs and BMDCs.

NF-κB luciferase reporter assay
-------------------------------

IEC-18 cells were infected for 16 h with an adenoviral vector encoding an NF-κB-luciferase reporter gene (Ad5κB-LUC) as previously described[@b40]. Cells were pretreated with various concentrations of oxymatrine for 1 h, followed by stimulation with LPS (5 μg/mL) for 8 h. Cell extracts were prepared using luciferase cell lysis buffer (PharMingen, San Digeo, CA). Luciferase assays were performed using an LMax luminometer microplate reader (Molecular Devices, Sunnyvale, CA), and results were normalized for extract protein concentrations measured with the Bio-Rad protein assay kit (Bio-Rad, Hercules, CA) as previously described[@b41].

NF-κB immunofluorescence and Ki-67 immunohistochemistry
-------------------------------------------------------

IEC-6 cells were pretreated with oxymatrine (4 mg/mL) for 1 hr and stimulated with LPS (5 μg/mL) for 30 min or 1 hr, cells were fixed and permeabilized using 100% ice-cold methanol for 10 min at 4°C. Immunofluorescent staining using p65 antibody (Millipore, anti-NF-κB CT, Billerica, MA) was performed as previously described[@b38]. Nuclear p65 aggregation was estimated by counting 3 random fields of view per slide utilizing an Olympus IX70 inverted epifluorescent microscope and data were reported as percentage of nuclear p65 positive cells.

Immunohistochemistry (IHC) was performed using tissue sections deparaffinized in xylene and rehydrated using a series of graded alcohol washes. Sections were probed using a Ki-67 monoclonal antibody (Dako, Carpinteria, CA) and biotinylated secondary antibody (Vector Laboratories, Burlingame, CA) as previously described[@b42].

Western blot analysis
---------------------

Proteins were extracted with RIPA buffer and quantified using Bio-Rad protein assay (Bio-Rad). Proteins (20 μg/sample) were separated by SDS-PAGE and transferred to nitrocellulose membranes (Hybond-C Extra Amersham Biosciences, Piscataway, NJ). Antibodies to phospho-IκBα (Cell Signaling Technology, Danvers, MA), phospho-p38MAPK and total p38MAPK (Cell Signaling) were diluted 1∶500 in 5% bovine serum albumin/TBS-tween and antibodies to total IκBα (Cell Signaling) 1∶1000 and β-Actin (Santa Cruz Biotechnology, La Jolla, CA) 1∶10,000 in 5% milk/TBS-tween. Immunoreactive proteins were detected using the enhanced chemiluminescence light (ECL) detecting kit (Amersham, GE Healthcare Biosciences, Pittsburgh, PA) as previously described[@b38]. Densitometric values of immunoblot signals were obtained from 3 separate experiments using Adobe Photoshop.

Chromatin immunoprecipitation assay
-----------------------------------

Chromatin immunoprecipitations were performed as previously described[@b39][@b43]. Briefly, IEC-18 cells were stimulated with LPS (5 μg/mL) alone or with oxymatrine (4 mg/mL) for 30 and 60 min, and ChIP assay performed using a ChIP assay kit (Upstate-Cell Signaling Solutions, Temecula, CA) according to the manufacturer\'s specifications. Immunoprecipitation was carried out overnight with 2 μg of p65 (c-20; Santa Cruz Biotechnology) or RNA polymerase II (c-21; Santa Cruz Biotechnology) antibodies. PCR was performed with total input DNA (5 μl) and immunoprecipitated DNA (5 μl) using cxcl2 promoter-specific primers: CXCL2 promoter forward, 5′-CCTTCTTCCTGATGCAGGG-3′; CXCL2 promoter reverse, 5′-AGTCTGGGGCTGTGAGGTC-3′. Thermal cycle conditions were as follows: one cycle of 5 min of 94°C, and 40 cycles of 94°C for 30 s, 60°C for 30 s, and 72°C for 30 s followed by an extension of 7 min at 72°C. The PCR products were subjected to electrophoresis on 2% agarose gels containing GelStar fluorescent dye (Cambrex BioScience, Rockland, ME). Fluorescence staining was captured using an Alpha Imager 2000 (Alpha Innotech, Santa Clara, CA).

Reverse transcriptase PCR and real time PCR
-------------------------------------------

RNA was isolated using Trizol reagent (Invitrogen, Grand Island, NY) and manufacturer\'s recommended protocol. cDNA was prepared using reverse-transcriptase amplification kit (Invitrogen) and cytokine expression quantitated using real-time PCR (Applied Biosystems 7900HT Fast Real-Time PCR System) and SYBR Green PCR Master Mix kit (Qiagen, Valencia, CA). Primer sequences for rat Cxcl-2, murine TNFα, IL-6, IL-1β and GAPDH primers were used as previously described[@b24]. Sequences for rat TNFα[@b44], GAPDH[@b45], IL-6 and IL-1β were also previously described[@b46].

DSS colitis
-----------

8--12 week-old conventionally raised wild-type C57BL/6 mice or NF-κB^EGFP^ mice (for NF-κB transcriptional studies) were exposed to 3% DSS (TdB Consultancy, Uppsala, Sweden) in drinking water as previously described[@b47]. Oxymatrine and saline solutions were prepared daily, and sterilized using a 0.22 μm filter (Fisher Scientific, Pittsburg, PA) prior to intraperitoneal injection (i.p). Oxymatrine dosage (50 and 200 mg/kg) were selected based on previous *in vivo* studies[@b8][@b9][@b10][@b12][@b14]. Mice were injected with oxymatrine 2 days prior to exposure to DSS. Mice were monitored daily for weight loss as well as signs of rectal bleeding and diarrhea. At d 9 of DSS administration, mice were sacrificed, sections were taken from the distal, proximal colon and cecum for histological assessment. EGFP expression was imaged as described previously[@b24]. Mice were sacrificed at the end of DSS-exposure according to our IACUC-approved protocol and colons excised. Tissues were prepared for swiss-roll analysis as previously described[@b47]. Analysis of histopathology was determined using the scoring system developed by Cooper[@b48] and Dieleman[@b49] and modified by Williams[@b50] using a 0 to 40 scale as previously described[@b47].

Statistics
----------

Data are represented as means ± SEM. Statistics were calculated using GraphPad Prism 5.0d software, utilizing non-parametric 2-tailed *t* tests, One-way ANOVA or Mann-Whitney analysis and considered significant if p values were \<0.05.
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![Oxymatrine inhibits LPS-mediated *Cxcl2*, *Il6* and *Tnfα* expression in IEC-6 Cells.\
IEC-6 cells were stimulated for 1 and 4 hr with 5 μg/mL LPS ± 4 mg/mL OMT and real-time PCR performed to analyze *Cxcl2*, *Tnfα*, *Il6* and *Il1b* mRNA accumulation standardized to *Gapdh* expression. Measurements expressed as fold induction over control unstimulated cells. Results combined from 2 independent experiments, and represent 3 independent experiments. \*p \< 0.05, \*\*p \< 0.01 compared to LPS controls.](srep01629-f1){#f1}

![Oxymatrine inhibits LPS-induced pro-inflammatory cytokine expression in BMDCs.\
Naïve BMDCs were stimulated with 1 μg/mL LPS for 1 or 4 h ± 4 mg/mL OMT and real-time PCR performed to analyze *Il6*, *Il1b* and *Tnfα* mRNA accumulation standardized to *Gapdh* expression. Results are combined data from 3 independent experiments. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001 compared to LPS control.](srep01629-f2){#f2}

![Oxymatrine inhibits NF-κB activation independent of IκBα phosphorylation.\
(a) IEC-18 cells were transduced using an NF-κB luciferase construct and stimulated with 5 μg/mL LPS ± 4 mg/mL OMT. Luciferase production was measured and reported as fold induction over control normalized to amount of extract protein (light units/μg). Results are combined from 3 independent experiments. (b) Western blot analysis of phospho-IκBα and total IκBα was performed using IEC-18 cells stimulated with 5 μg/mL LPS for 30, 60 or 90 minutes ± 4 mg/mL OMT. β-Actin was used as a loading control. Densitometric analysis of protein levels is shown on the right side. Representative of 3 independent experiments. (c) Western blot analysis of phospho-p38, total p38 and β-Actin was performed using IEC-6 cells stimulated with LPS for 30 or 60 minutes ± OMT. Densitometric analysis of protein levels is shown on the right side. Representative of 3 independent experiments. \*\*p \< 0.01 compared to LPS control.](srep01629-f3){#f3}

![Oxymatrine inhibits p65 nuclear translocation.\
(a) IEC-6 cells were treated with 5 μg/mL LPS ± 4 mg/mL OMT for 30 minutes. Cells were fixed, permeabilized and immunofluorescent staining performed for p65 (inner panels). Hoescht nuclear staining was also performed (outer panels). Representative of 3 independent experiments. (b) p65 cytosolic and nuclear quantifications were measured as p65 nuclear accumulation in 3 random fields of view per slide. Graph represents combined data from 3 independent experiments. (c) Chromatin immunoprecipitation (ChIP) analysis of p65 binding to the *Cxcl2* promoter of IEC-18 cells stimulated with LPS ± OMT for 30 and 60 min. PCR amplification products were separated using agarose gel electrophoresis and gel scan results are presented in inverse color. Representative of 2 independent experiments. \*\*P \< 0.01 compared to LPS control.](srep01629-f4){#f4}

![Oxymatrine ameliorates DSS-induced pathology.\
WT C57BL/6 mice were pre-treated with saline or OMT for 2 days prior to addition of 3% DSS to drinking water. (a) Daily weights were measured (n = 5-7/group) and plotted as percentage bodyweight change from initial weight, expressed as group % mean ± SEM. (b) Representative colon swiss roll sections stained with H&E (original magnification 100X). (c) Group colon histopathological scores. Bars represent mean ± SEM. (d) Real-time PCR analysis of colonic tissue *Tnf*, *Il6* and *Il1b* expression standardized to *Gapdh* expression. Expressed as fold induction over mock treated control mice. Representative of 2 independent experiments. (e) Immunhistochemical analysis of Ki-67 expression was performed using colon sections from control untreated, DSS-treated and DSS + 200 mg/Kg OMT-treated mice. Graph represents quantification of Ki-67^+^ cells within intact distal colonic crypts. 3 sections were stained and counted per condition. (f) Macroscopic analysis of representative colons from experimental NF-κB^EGFP^ mouse groups, fluorescent analysis (right panel). Representative of 2 independent experiments. \*p \< 0.05, \*\*p \< 0.01 compared to DSS-only control.](srep01629-f5){#f5}
